ZAI LAB LIMITED Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
ZAI LAB LIMITED (ZLAB) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $2.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- ZAI LAB LIMITED share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $2.20M, a 8048.15% increase year-over-year.
- ZAI LAB LIMITED share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $2.27M.
- ZAI LAB LIMITED share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $8.19M.
- ZAI LAB LIMITED share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $27.00K.
- ZAI LAB LIMITED share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $8.22M.
- ZAI LAB LIMITED share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $8.98M, a 18.52% increase from fiscal 2022.
- ZAI LAB LIMITED share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $7.58M, a 77.07% increase from fiscal 2021.
- ZAI LAB LIMITED share-based payment arrangement, decrease for tax withholding obligation for fiscal 2021 was $4.28M.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.20M 10-Q · filed 2026-08-06 | $4.47M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.27M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $8.22M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $8.19M 10-Q · filed 2025-11-06 | $8.22M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $27.00K 10-Q · filed 2026-08-06 | |||
| 2023-12-31 | $8.98M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $264.00K 10-Q · filed 2024-11-12 | $3.80M derived: sum of 2 quarters · filed 2024-11-12 | $8.93M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $3.54M 10-Q · filed 2024-11-12 | $8.67M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $5.13M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $7.58M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $327.00K 10-Q · filed 2023-11-07 | $7.11M derived: sum of 2 quarters · filed 2023-11-07 | $7.18M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $6.78M 10-Q · filed 2023-11-07 | $6.85M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $68.00K 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $4.28M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $2.61M 10-Q · filed 2022-11-09 | $3.53M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $924.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |